As of Apr 28
| -0.60 / -1.81%|
The 6 analysts offering 12-month price forecasts for Supernus Pharmaceuticals Inc have a median target of 34.00, with a high estimate of 45.00 and a low estimate of 26.00. The median estimate represents a +4.29% increase from the last price of 32.60.
The current consensus among 6 polled investment analysts is to Buy stock in Supernus Pharmaceuticals Inc. This rating has held steady since April, when it was unchanged from a Move your mouse over past
months for detail
Move your mouse over a quarter or year to see how estimates have changed over time.